Custom Peptide Libraries
Genscript Corporation SARS-CoV-2 Spike protein RBD
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases The spike protein mutation N501Y is one of six key contact residues within the receptor-binding domain (RBD) and has been identified as increasing binding affinity to human and murine ACE2
Bioss Prostate Secretory Protein/PSP
Prostate Secretory Protein/PSP Primary Antibody Unconjugated Host Species Rabbit Target Species Human Clonality Monoclonal Applications WB IHC-P IHC-F IP IF RecombinantConcentration 1ug/ul Size 100 ul Storage Buffer 10mM phosphate buffered saline(pH 7 4) with 150mM sodium chloride 0 05% BSA 0 02% sodium azide and 50% glycerol
Sino Biological HSV 2 (strain 333) gE/glycoprotein E Protein (His Tag)(MALS-verified) 100µg
A DNA sequence encoding the HSV 2 ((strain 333) (HSV2)) gE/glycoprotein E (translated amino acids of AKC42830.1) (Met1-Arg417) was expressed with a polyhistidine tag at the C-terminus.
Sino Biological Influenza A H1N1 (A/Wisconsin/67/2022) Nucleoprotein/NP Protein (His & AVI Tag), Biotinylated 20µg
A DNA sequence encoding the Influenza A virus ((A/Wisconsin/67/2022) (H1N1)) nucleoprotein (EPI2224781) (Met1-Asn498) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed.
Abcam DADLE, delta-Opioid peptide agonist, 5MG
MW 569.66 g/mol, Purity >95%. Synthetic δ-opioid peptide agonist, with some activity at μ-opioid receptors. Neuro- and tissue-protective properties. Attenuates mRNA expression of p53 and c-fos.
The product is subject to the following: Abcam Restricted Use Statement
Biolegend Brilliant Violet 510TM anti-mo
Brilliant Violet 510™ anti-mouse I-Ak (Aβk) [10-3.6]; Isotype: Mouse (CWB) IgG2a, κ; Reactivity: Mouse; Apps: FC; Size: 50 μg
Abcam DAMGO, mu opioid receptor agonist, 1MG
MW 513.6 Da, Purity >95%. DAMGO, mu opioid receptor agonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Genscript Corporation HEK293T/Spike Stable Cell Line
Recombinant HEK293T cells stably overexpress coronavirus SARS-CoV-2 spike protein on the surface The surface expression of SARS-CoV-2 spike protein is validated by FACS analysis This stable cell line product is designed for screening antibodies against SARS-CoV-2 spike protein as well as for measuring binding affinity and stability of antibody based biologics that bind with spike protein GenScript also offers spike protein expressing CHO-K1 stable cell line (Cat No M00803) for SARS-CoV-2 study
INTACT GENOMICS INC ER2738 Phage Disp 12 x 50ul
ig ER2738 Phage Display Chemically Competent Cells 12x50ul
Sino Biological Influenza A H1N1 (A/Victoria/4897/2022) Nucleoprotein / NP Protein (His & AVI Tag), Biotinylated 20µg
A DNA sequence encoding the Influenza A virus ((A/Victoria/4897/2022 (H1N1)) Nucleoprotein / NP (EPI2603713) (Met1-Asn498) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed.
Genscript Corporation SARS-CoV-2 Spike protein RBD-H
BA 2 differs from BA 1 in its genetic sequence including some amino acid differences in the spike protein and other proteins Studies have shown that BA 2 has a growth advantage over BA 1 Studies are ongoing to understand the reasons for this growth advantage but initial data suggest that BA 2 appears inherently more transmissible than BA 1 which currently remains the most common Omicron sublineage reported This difference in transmissibility appears to be much smaller than for example the difference between BA 1 and Delta Further although BA 2 sequences are increasing in proportion relative to other Omicron sublineages (BA 1 and BA 1 1) there is still a reported decline in overall cases globally
Cayman Chemical AcMNPV Major Envelope Glycopr
A TRPM8 antagonist (IC50s 13 and 20 for the human and rat channels respectively) selective for TRPM8 over TRPV1 TRPV3 TRPV4 and TRPA1 (IC50s 20 20 20 and 40 UM respectively) as well as a panel of 100 kinases and 144 additional targets at 1 and 10 UM respectively decreases icilin-induced wet-dog shakes in rats from 0.6-3 mg/kg
Cayman Chemical AcMNPV Major Envelope Glycopr
A TRPM8 antagonist (IC50s 13 and 20 for the human and rat channels respectively) selective for TRPM8 over TRPV1 TRPV3 TRPV4 and TRPA1 (IC50s 20 20 20 and 40 UM respectively) as well as a panel of 100 kinases and 144 additional targets at 1 and 10 UM respectively decreases icilin-induced wet-dog shakes in rats from 0.6-3 mg/kg
